Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969136 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT01969136 is a Phase 3 study that was terminated before completion, run by FORUM Pharmaceuticals. The registered enrollment target is 403 participants.
The verdict
NCT01969136, a Phase 3 study, was terminated before completion, sponsored by FORUM Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
Interventions
- DRUG Placebo
- DRUG Drug: EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969136
The ClinicalTrials.gov registry entry for NCT01969136 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01969136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969136 about?
NCT01969136 is a clinical study titled "Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
What is the current status of trial NCT01969136?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2013-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01969136?
The interventions under investigation include: Placebo (DRUG), Drug: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01969136?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.